Fierce Biotech March 13, 2024
Artificial intelligence and machine learning technology are now seemingly sprinkled across all corners of drug discovery, but one biotech is wielding large language models to advance a class of medicines that’s just now blossoming.
Mindstate Design Labs has submitted its first IND, asking the FDA to greenlight a clinical trial for its lead asset targeting 5-MeO-MiPT, also known as moxy, a psychedelic selected from more than 70,000 “trip reports” to classify states of consciousness. Those reports—often detailed, self-reported accounts from psychedelic users—were plucked from all regions of the internet, including the social media platform Reddit, drug forums, clinical data sets and the dark web.
According to CEO Dillan DiNardo, those 70,000 reports represent basically “every trip report in existence.”...
Today's Sponsors
Today's Sponsor